Excellent
Mostly Aligned
Patient Risk:
Low
Summary
Three claims about initial FDA approval and historical indications are not present in the current label; the evaluation correctly marks them as absent_from_label.
Category Scores
Accurate Statements
Unsupported Statements
Keytruda (pembrolizumab) received its initial FDA approval in September 2014.
Not supported by current labeling; labeling does not provide historical approval dates.
The initial FDA-approved indication was unresectable or metastatic melanoma that had progressed after ipilimumab (Yervoy).
Not supported by current labeling; labeling lists unresectable or metastatic melanoma as an indication but does not reference prior ipilimumab therapy.
The initial FDA-approved indication included unresectable or metastatic melanoma that had progressed after ipilimumab plus, if BRAF V600 mutation–positive, a BRAF inhibitor.
Not supported by current labeling; labeling does not describe historical sequencing with ipilimumab/BRAF inhibitors.
Contradictions
Important Omissions
Current labeling includes additional indications such as adjuvant melanoma treatment (Stage IIB, IIC, III) after complete resection; these are not discussed in the claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims concern regulatory history and current indications only; no safety or management recommendations are asserted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement